SCHEMBL2882151

SCHEMBL2882151

CC(C)(C)[Si](C)(C)Oc1ccc(CCO)cc1

nearest known ligand 0.50

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 2/20 0.50
PREP P48147 4/20 0.43
CA2 P00918 1/20 0.41
CA12 O43570 4/20 0.40
CA1 P00915 4/20 0.40
CA9 Q16790 4/20 0.40
CYP4F2 P78329 3/20 0.40
CYP4A11 Q02928 3/20 0.40
TDP1 Q9NUW8 1/20 0.38
PTGS2 P35354 2/20 0.36
HRH3 Q9Y5N1 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2675281 0.90 PPARA (0.53) PPARAPREPCA2CA12CA1
SCHEMBL13159232 0.88 PPARA (0.48) PPARAPREPCA2CA12CA1
SCHEMBL25496223 0.87 PPARA (0.47) PPARAPREPCA2CA12CA1
SCHEMBL318210 0.85 PPARA (0.47) PPARAPREPCA12CA1CA9
SCHEMBL3843622 0.84 PREP (0.44) PPARAPREPCA12CA1CA9
SCHEMBL2450429 0.82 TAAR1 (0.53) PREP
SCHEMBL17661806 0.81 PREP (0.43) PPARAPREPCA12CA1CA9
SCHEMBL4521924 0.81 PREP (0.42) PPARAPREPCA12CA1CA9
SCHEMBL2997961 0.81 PREP (0.42) PPARAPREPCA12CA1CA9
SCHEMBL26781085 0.81 PREP (0.49) PREPCA12CA1CA9TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230365873-A1 NITROGEN-FREE HYDROGEN SULPHIDE AND MERCAPTANS SCAVENGERS TOTALENERGIES ONETECH (FR) 2023-11-16 US disclosed
US-20230365873-A1 NITROGEN-FREE HYDROGEN SULPHIDE AND MERCAPTANS SCAVENGERS TOTALENERGIES ONETECH (FR) 2023-11-16 US disclosed
EP-3774789-A1 BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE Arvinas Operations, Inc. (US) 2021-02-17 EP disclosed
WO-2019195201-A1 BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. (US) 2019-10-10 WO disclosed
US-8314087-B2 Nitrogen-containing heterocyclyl ketones and methods of use AMGEN INC. (US) 2012-11-20 US disclosed
US-8314087-B2 Nitrogen-containing heterocyclyl ketones and methods of use AMGEN INC. (US) 2012-11-20 US disclosed
US-20100216758-A1 Pyridone Compounds MSD K.K. (JP) 2010-08-26 US disclosed
EP-2114898-A2 NITROGEN-CONTAINING HETEROCYCLYL KETONES AND THEIR USE AS C-MET INHIBITORS Amgen Inc. (US) 2009-11-11 EP disclosed
US-20090131372-A1 PHOSPHONATE ANALOGS FOR TREATING METABOLIC DISEASES CHEN JAMES M 2009-05-21 US disclosed
US-20080280917-A1 Nitrogen-Containing heterocyclyl ketones and methods of use AMGEN INC. (US) 2008-11-13 US disclosed
EP-1916239-A1 PYRIDONE COMPOUND BANYU PHARMACEUTICAL CO., LTD. (JP) 2008-04-30 EP disclosed
EP-1497261-B1 PHENETHANOLAMINE DERIVATIVES GLAXO GROUP LTD (GB) 2007-12-19 EP disclosed
US-7271197-B2 Phenethanolamine derivatives GLAXO GROUP LIMITED (GB) 2007-09-18 US disclosed
US-20050256201-A1 Phenethanolamine derivatives GLAXO GROUP LIMITED 2005-11-17 US disclosed
EP-1497261-A1 PHENETHANOLAMINE DERIVATIVES GLAXO GROUP LIMITED (GB) 2005-01-19 EP disclosed
WO-2003091204-A1 PHENETHANOLAMINE DERIVATIVES GLAXO GROUP LIMITED (GB) 2003-11-06 WO disclosed
US-4994476-A Hypotensive agents BRISTOL-MYERS COMPANY (US) 1991-02-19 US disclosed
EP-0201558-A4 DIHYDROPYRIDIN-3,5-DICARBOXYLATES INCORPORATING ARYLOXYPROPANOLAMINE MOIETIES. BRISTOL MYERS CO (US) 1988-04-13 EP disclosed
EP-0201558-A1 DIHYDROPYRIDIN-3,5-DICARBOXYLATES INCORPORATING ARYLOXYPROPANOLAMINE MOIETIES Bristol-Myers Squibb Company (US) 1986-11-20 EP disclosed
WO-1986002640-A1 DIHYDROPYRIDIN-3,5-DICARBOXYLATES INCORPORATING ARYLOXYPROPANOLAMINE MOIETIES BRISTOL-MYERS COMPANY (US) 1986-05-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230365873-A1 NITROGEN-FREE HYDROGEN SULPHIDE AND MERCAPTANS SCAVENGERS SIGMAR1, GRHPR, CBR1 PPARA 1717/4885PREP 2498/4885CA2 1177/4885
US-20080280917-A1 Nitrogen-Containing heterocyclyl ketones and methods of use HGF, HGFAC, MET PPARA 554/4885PREP 568/4885CA2 3315/4885
US-20100216758-A1 Pyridone Compounds NPY1R, MC5R, MC1R PPARA 1244/4885PREP 2250/4885CA2 4358/4885
US-20090131372-A1 PHOSPHONATE ANALOGS FOR TREATING METABOLIC DISEASES PHOSPHO1, G6PC1, PC PPARA 234/4885PREP 1256/4885CA2 2638/4885
US-20050256201-A1 Phenethanolamine derivatives PNMT, PHOSPHO1, NAPEPLD PPARA 487/4885PREP 222/4885CA2 2017/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.